A detailed history of Assetmark, Inc transactions in Guardant Health, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 7 shares of GH stock, worth $203. This represents 0.0% of its overall portfolio holdings.

Number of Shares
7
Holding current value
$203
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$22.3 - $36.29 $156 - $254
7 New
7 $0
Q1 2024

May 06, 2024

SELL
$17.13 - $26.91 $282,662 - $444,041
-16,501 Reduced 95.94%
698 $14,000
Q4 2023

Feb 09, 2024

BUY
$21.58 - $29.5 $102,677 - $140,361
4,758 Added 38.24%
17,199 $465,000
Q3 2023

Oct 27, 2023

BUY
$25.8 - $39.97 $68,602 - $106,280
2,659 Added 27.18%
12,441 $368,000
Q2 2023

Aug 11, 2023

BUY
$20.94 - $38.01 $109,579 - $198,906
5,233 Added 115.04%
9,782 $350,000
Q1 2023

May 05, 2023

BUY
$22.92 - $33.76 $11,276 - $16,609
492 Added 12.13%
4,549 $106,000
Q4 2022

Feb 10, 2023

BUY
$25.44 - $59.78 $30,935 - $72,692
1,216 Added 42.8%
4,057 $110,000
Q3 2022

Nov 01, 2022

BUY
$43.66 - $61.0 $87,407 - $122,122
2,002 Added 238.62%
2,841 $153,000
Q2 2022

Aug 03, 2022

SELL
$28.82 - $77.35 $674,791 - $1.81 Million
-23,414 Reduced 96.54%
839 $34,000
Q1 2022

May 13, 2022

BUY
$48.25 - $100.49 $535,237 - $1.11 Million
11,093 Added 84.29%
24,253 $1.61 Million
Q4 2021

Feb 14, 2022

BUY
$88.71 - $120.43 $1.11 Million - $1.51 Million
12,538 Added 2015.76%
13,160 $1.32 Million
Q3 2021

Nov 12, 2021

BUY
$98.77 - $132.17 $61,434 - $82,209
622 New
622 $78,000
Q1 2021

May 14, 2021

SELL
$127.04 - $179.1 $2,921 - $4,119
-23 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$99.96 - $135.93 $2,299 - $3,126
23 New
23 $3,000

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $2.98B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Assetmark, Inc Portfolio

Follow Assetmark, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.